Associations of CXCL16/CXCR6 with carotid atherosclerosis in patients with metabolic syndrome

Clinical Nutrition

Volumn 32, Issue 5, 2013, Pages 849-854

  Lv, Yongqing ^a,b,c   Hou, Xiaoyang ^a,b   Ti, Yun ^a,b   Bu, Peili ^a,b  

^a BEIJING HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

^c CNPC Jichai Power Equipment Company   (China)

Author keywords

Carotid atherosclerosis; CXCL16; CXCR6; Metabolic syndrome; T lymphocyte cell

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; SOLUBLE CXCL16; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CXCL16 GENE; CXCR6 GENE; DISEASE ASSOCIATION; DISEASE MARKER; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; INTERNAL MEMBRANE THICKNESS; MALE; METABOLIC SYNDROME X; NATURAL KILLER T CELL; NERVOUS SYSTEM PARAMETERS; PLAQUE INDEX; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; T LYMPHOCYTE ACTIVATION; WAIST CIRCUMFERENCE;

CAROTID ATHEROSCLEROSIS; CXCL16; CXCR6; METABOLIC SYNDROME; T LYMPHOCYTE CELL;

AGED; BIOLOGICAL MARKERS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHEMOKINES, CXC; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KILLER CELLS, NATURAL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, CHEMOKINE; RECEPTORS, SCAVENGER; RECEPTORS, VIRUS; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SOLUBILITY; T-LYMPHOCYTES; UP-REGULATION;

EID: 84883555068     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2013.01.008     Document Type: Article

References (23)

1. Holt R.I. International Diabetes Federation re-defines the metabolic syndrome. Diabetes Obes Metab 2005, 7:618-620.
2. Leoncini G., Ratto E., Viazzi F., Vaccaro V., Parodi D., Parodi A., et al. Metabolic syndrome is associated with early signs of organ damage in diabetes, hypertensive patients. JIntern Med 2005, 257:454-460.
3. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. NEngl J Med 2005, 352:1685-1695.
4. Wiesel M., Oxenius A. From crucial to negligible: functional CD8+ T-cell responses and their dependence on CD4+ T-cell help. Eur J Immunol 2012, 42:1080-1088.
5. Shimaoka T., Nakayama T., Fukumoto N., Kume N., Takahashi S., Yamaguchi J., et al. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. JLeukoc Biol 2004, 75:267-274.
6. van Oostrom O., Velema E., Schoneveld A.H., de Vries J.P., de Bruin P., Seldenrijk C.A., et al. Age-related changes in plaque composition: a study in patients suffering from carotid artery stenosis. Cardiovasc Pathol 2005, 14:126-134.
7. Yamauchi Ryoko, Tanaka Makoto, Kume Noriaki, Minami Manabu, Kawamoto Takahiro, Togi Kiyonori, et al. Upregulation of SR-PSOX/CXCL16 and recruitment of CD8+ T cells in cardiac valves during inflammatory valvular heart disease. Arterioscler Thromb Vasc Biol 2004, 24:282-287.
8. Wilbanks A., Zondlo S.C., Murphy K., Mak S., Soler D., Langdon P., et al. Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. JImmunol 2001, 166:5145-5154.
9. Matloubian M., David A., Engel S., Ryan J.E., Cyster J.G. Atransmembrane CXCchemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000, 1:298-304.
10. Moore K.J., Freeman M.W. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006, 26:297-300.
11. Drakopoulou M., Toutouzas K., Michelongona A., Tousoulis D., Stefanadis C. Vulnerable plaque and inflammation: potential clinical strategies. Curr Pharm Des 2011, 17:4190-4209.
12. Chandraskar B., Bysani S., Mummidi S. CLXL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I Kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. JBiol Chem 2004, 279:3188-3196.
13. Barlic J., Zhu W., Murphy P.M. Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion. JImmunol 2009, 182:7928-7936.
14. Shashkin P., Simpson D., Mishin V., Chesnutt B., Ley K. Expression of CXCL16 in human T cells. Arterioscler Thromb Vasc Biol 2003, 23:148-149.
15. Campbell K.A., Lipinski M.J., Doran A.C., Skaflen M.D., Fuster V., McNamara C.A. Lymphocytes and the adventitial immune response in atherosclerosis. Circ Res 2012, 110:889-900.
16. Koenig W., Khuseyinova N. Biomaker of atherosclerotic piaque instability and rupture. Arterioscler Thromb Vasc Biol 2007, 27:15-26.
17. Lehrke M., Millington S.C., Lefterova M., Cumaranatunge R.G., Szapary P., Wilensky R., et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. JAm Coll Cardiol 2007, 49:442-449.
18. Whitman S.C., Ravisankar P., Elam H., Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol 2000, 157:1819-1824.
19. Aslanian A.M., Charo I.F. Targeted disruption of the scavenger receptor andchemokine CXCL16 accelerates atherosclerosis. Circulation 2006, 114:583-590.
20. Lundberg G.A., Kellin A., Samnegård A., Lundman P., Tornvall P., Dimmeler S., et al. Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene. JIntern Med 2005, 257:415-422.
21. Koprak S., Matheravidathu S., Springer M., Gould S., Dumont F.J. Down-regulation of cell surface CXCR6 expression during T cell activation is predominantly mediated by calcineurin. Cell Immunol 2003, 223:1-12.
22. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
23. Saely C.H., Koch L., Schmid F., Marte T., Aczel S., Langer P., et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 2006, 29:901-907.